Former Dendreon CEO Gold's New Cell Therapy Business Partners With Kite
This article was originally published in Scrip
Executive Summary
With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.
You may also be interested in...
Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.